Dextech Medical AB (NGM: DEX)
Sweden
· Delayed Price · Currency is SEK 4.100
+0.020 (0.49%)
At close: Nov 20, 2024
Dextech Medical AB Income Statement
Financials in millions SEK. Fiscal year is July - June.
Millions SEK. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 4.32 | 5.39 | 8.71 | 3.12 | 0.63 | 0.6 | Upgrade
|
| Revenue Growth (YoY) | -54.07% | -38.18% | 179.60% | 390.65% | 6.48% | -73.66% | Upgrade
|
| Cost of Revenue | - | - | - | - | - | 1.98 | Upgrade
|
| Gross Profit | 4.32 | 5.39 | 8.71 | 3.12 | 0.63 | -1.38 | Upgrade
|
| Selling, General & Admin | 6.15 | 7.25 | 10.59 | 5.36 | 2.58 | 0.72 | Upgrade
|
| Operating Expenses | 10.08 | 10.93 | 13.65 | 8.39 | 6.71 | 6.33 | Upgrade
|
| Operating Income | -5.76 | -5.55 | -4.94 | -5.27 | -6.08 | -7.71 | Upgrade
|
| Interest Expense | - | - | - | - | -0 | -0 | Upgrade
|
| Interest & Investment Income | 0.83 | 0.84 | 0.35 | - | - | - | Upgrade
|
| Pretax Income | -4.93 | -4.71 | -4.59 | -5.27 | -6.08 | -7.71 | Upgrade
|
| Net Income | -4.93 | -4.71 | -4.59 | -5.27 | -6.08 | -7.71 | Upgrade
|
| Net Income to Common | -4.93 | -4.71 | -4.59 | -5.27 | -6.08 | -7.71 | Upgrade
|
| Shares Outstanding (Basic) | 19 | 19 | 18 | 17 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 19 | 18 | 17 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | 2.51% | 2.51% | 8.02% | 14.72% | -0.11% | 1.20% | Upgrade
|
| EPS (Basic) | -0.26 | -0.25 | -0.25 | -0.31 | -0.41 | -0.52 | Upgrade
|
| EPS (Diluted) | -0.26 | -0.25 | -0.25 | -0.31 | -0.41 | -0.52 | Upgrade
|
| Free Cash Flow | -1.31 | -0.81 | -1.55 | -2 | -2 | -2.26 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.04 | -0.08 | -0.12 | -0.13 | -0.15 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -231.26% | Upgrade
|
| Operating Margin | -133.11% | -103.04% | -56.70% | -169.14% | -956.76% | -1293.51% | Upgrade
|
| Profit Margin | -113.95% | -87.38% | -52.70% | -169.14% | -956.77% | -1293.53% | Upgrade
|
| Free Cash Flow Margin | -30.26% | -15.00% | -17.82% | -64.20% | -314.94% | -379.13% | Upgrade
|
| EBITDA | -5.4 | -5.39 | -4.77 | -5.03 | -5.81 | -7.44 | Upgrade
|
| EBITDA Margin | -124.91% | -100.17% | -54.78% | -161.32% | - | - | Upgrade
|
| D&A For EBITDA | 0.35 | 0.15 | 0.17 | 0.24 | 0.27 | 0.28 | Upgrade
|
| EBIT | -5.76 | -5.55 | -4.94 | -5.27 | -6.08 | -7.71 | Upgrade
|
| EBIT Margin | -133.11% | -103.04% | -56.70% | -169.14% | - | - | Upgrade
|
| Revenue as Reported | 5.39 | 5.39 | 8.71 | 3.12 | 0.63 | 0.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.